Dr. Ebbinghaus is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Cottman Avenue
Fox Chase Cancer Cenetr
Philadelphia, PA 19111Phone+1 215-728-6900Fax+1 215-728-3639
Education & Training
University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 1993 - 1996- University of Alabama Medical CenterResidency, Internal Medicine, 1989 - 1993
University of Missouri Kansas City School of MedicineClass of 1989
Certifications & Licensure
PA State Medical License 2007 - 2024
AZ State Medical License 2000 - 2009
AL State Medical License 1990 - 2007
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Study Evaluating the Safety and Tolerability of L-377202 Start of enrollment: 1999 Mar 01
Publications & Presentations
PubMed
- 2629 citationsSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaOmid Hamid, Caroline Robert, Adil Daud, F. Stephen Hodi, Wen-Jen Hwu
The New England Journal of Medicine. 2013-07-10 - 4131 citationsPembrolizumab versus Ipilimumab in Advanced MelanomaCaroline Robert, Jacob Schachter, Georgina V. Long, Ana Arance, Jean-Jacques Grob
The New England Journal of Medicine. 2015-06-24 - 1363 citationsAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trialCaroline Robert, Antoni Ribas, Jedd D. Wolchok, F. Stephen Hodi, Omid Hamid
Lancet. 2014-09-20
Authored Content
- Outcomes by Line of Therapy and Programmed Death Ligand 1 Expression in Patients with Advanced Melanoma Treated with Pembrolizumab or Ipilimumab in KEYNOTE-006: A Randomised Clinical TrialAugust 2018
Press Mentions
USFDA Accepts Application for Merck KEYTRUDA plus Chemotherapy as First Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaApril 13th, 2023- Merck Keytruda Gets Full USFDA Approval for Advanced MSI-H or dMMR Solid TumorsApril 1st, 2023
- Experts Discuss Importance of Cancer Screenings and Early DetectionAugust 11th, 2022
- Join now to see all
Grant Support
- Site Specific Alkylation Of The Her2/Neu PromoterNational Cancer Institute2002–2004
- Specific Inhibition Of Her2/Neu Transcription ElongationNational Cancer Institute2000–2002
- Specific Inhibition Of Her2/Neu Transcription ElongationNational Cancer Institute1998–2000
- Triplex Based Gene Therapy Of Breast And Ovarian CancerNational Cancer Institute1996–1998
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
